Remidio Inc., a leading health technology innovator, is making waves in the fight against global blindness caused by diabetic retinopathy, glaucoma, AMD, and cataracts. This quarter, Remidio Inc. is proud to announce the placement of its 1000th FOP-NM handheld fundus camera in the hands of healthcare providers across the United States.
The FOP-NM, the world’s first smartphone-based non-mydriatic fundus camera, is revolutionizing retinal examinations. By eliminating the need for patient dilation, it offers a convenient and efficient solution for retinal screening. Medical specialists and non-specialists alike can easily perform retinal exams anywhere, whether it’s within a clinic setting, at home, in emergency rooms, or even in remote rural healthcare centers.
One notable institution benefiting from Remidio’s FOP-NM is the University of Virginia. Dr. Arjun Dirghangi, Assistant Professor of Ophthalmology, expresses his satisfaction with the device: “Remidio’s FOP-NM is easy to use and easy to train on. Even trainees who have never used the system before can capture good images within 30 seconds to 2 minutes per eye. This technology has the potential to greatly improve access to screening.”
What sets the FOP-NM apart from other handheld retinal cameras is its exceptional image quality. In a clinical validation study published in Nature Eye, the FOP-NM’s image quality was deemed on par with the gold standard of imaging. This clinically validated technology, combined with its user-friendly interface, streamlines the screening process and ensures effortless image acquisition, even for novice users.
To achieve their goal of impacting the lives of nearly 30 million individuals at risk for diabetic retinopathy in the US, Remidio is open to collaborations with AI SaMD companies and care providers. The company’s hardware and telehealth platform are readily available for partnership opportunities, aiming to bring care closer to the patient. Moreover, Remidio’s devices are versatile enough to be used for various chronic conditions, promising early detection and timely intervention.
With a dedicated team of over 170 professionals, Remidio continues to pioneer advancements in retinal examination technology. Their mission is to build a healthier tomorrow by ensuring eye health for all. Through their accessible and user-friendly devices, Remidio has impacted the lives of over 15 million patients in more than 40 countries worldwide.
For more information, please contact:
Erik Hafkey
Chief Commercial Officer
[email protected]
+1-888-627-1416
Photo: Remidio’s FOP NM – [Link to the photo]
Logo: Remidio Innovative Solutions – [Link to the logo]
Source: Remidio Innovative Solutions
Remidio Inc., with its innovative retinal examination technology, is playing a crucial role in combating global blindness caused by diabetic retinopathy, glaucoma, AMD, and cataracts. The company recently achieved a significant milestone with the placement of its 1000th FOP-NM handheld fundus camera in the hands of healthcare providers across the United States.
The FOP-NM, the world’s first smartphone-based non-mydriatic fundus camera, is revolutionizing retinal examinations by eliminating the need for patient dilation. This feature offers a convenient and efficient solution for retinal screening, enabling both medical specialists and non-specialists to perform exams easily in various settings, including clinics, emergency rooms, and remote healthcare centers.
One notable institution benefiting from Remidio’s FOP-NM is the University of Virginia, where Dr. Arjun Dirghangi, Assistant Professor of Ophthalmology, has expressed satisfaction with the device. He highlights the ease of use and training, stating that even trainees who have never used the system before can capture high-quality images within a short timeframe. Dr. Dirghangi believes that this technology has the potential to significantly improve access to retinal screening.
The standout feature of the FOP-NM is its exceptional image quality, which was validated in a clinical study published in Nature Eye. The study confirmed that the FOP-NM’s image quality is comparable to the gold standard of imaging. This clinically validated technology, combined with its user-friendly interface, simplifies the screening process and ensures effortless image acquisition, even for inexperienced users.
Remidio is committed to addressing the needs of approximately 30 million individuals at risk for diabetic retinopathy in the US. To achieve this, the company is open to collaborations with AI SaMD (Artificial Intelligence Software as a Medical Device) companies and care providers. Remidio’s hardware and telehealth platform are available for partnership opportunities, aiming to bring care closer to the patient. Additionally, Remidio’s devices are versatile enough to be used for various chronic conditions, enabling early detection and timely intervention.
With a dedicated team of over 170 professionals, Remidio is continuously pioneering advancements in retinal examination technology. Their mission is to build a healthier tomorrow by ensuring eye health for all. To date, Remidio has positively impacted the lives of over 15 million patients in more than 40 countries worldwide.
As for the advantages of Remidio’s FOP-NM, it offers a convenient and efficient solution for retinal screening by eliminating the need for patient dilation. Its exceptional image quality, as validated in clinical studies, ensures accurate and reliable results. The user-friendly interface allows for easy adoption by both medical specialists and non-specialists, expanding access to retinal examinations. Furthermore, Remidio’s openness to collaborations with AI SaMD companies and care providers reflects their commitment to improving healthcare outcomes through innovative partnerships.
While Remidio’s FOP-NM brings numerous advantages, there may be some challenges and controversies associated with the subject. These could include concerns regarding the cost of the device, accessibility in low-income regions, and potential limitations in diagnosing complex retinal conditions. However, without specific information or reports, it is difficult to discuss these challenges in detail.
To learn more about Remidio Inc. and their retinal examination technology, you can visit their official website: Remidio Inc.